118 related articles for article (PubMed ID: 35778348)
21. Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy.
Westerman ME; Sharma V; Bailey GC; Boorjian SA; Frank I; Gettman MT; Thompson RH; Tollefson MK; Karnes RJ
Int Braz J Urol; 2019; 45(3):468-477. PubMed ID: 30676305
[TBL] [Abstract][Full Text] [Related]
22. Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.
Pompe RS; Karakiewicz PI; Tian Z; Mandel P; Steuber T; Schlomm T; Salomon G; Graefen M; Huland H; Tilki D
J Urol; 2017 Aug; 198(2):354-361. PubMed ID: 28216329
[TBL] [Abstract][Full Text] [Related]
23. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
24. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy.
Morlacco A; Dal Moro F; Rangel LJ; Carlson RE; Schulte PJ; Jeffrey KR
Urol Oncol; 2018 Dec; 36(12):528.e1-528.e6. PubMed ID: 30446466
[TBL] [Abstract][Full Text] [Related]
25. Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
Nunez Bragayrac LA; Murekeyisoni C; Vacchio MJ; Attwood K; Mehedint DC; Mohler JL; Azabdaftari G; Xu B; Kauffman EC
Prostate; 2017 Jul; 77(10):1076-1081. PubMed ID: 28547760
[TBL] [Abstract][Full Text] [Related]
26. The Impact of Repeat Prostate Biopsies on Oncologic, Pathological and Perioperative Outcomes after Radical Prostatectomy.
Rosenbaum CM; Mandel P; Tennstedt P; Boehm K; Chun FK; Graefen M; Heinzer H; Tilki D; Salomon G
J Urol; 2017 Jan; 197(1):103-108. PubMed ID: 27506693
[TBL] [Abstract][Full Text] [Related]
27. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
[TBL] [Abstract][Full Text] [Related]
28. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
29. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
[TBL] [Abstract][Full Text] [Related]
30. Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort.
Würnschimmel C; Pose RM; Wenzel M; Tian Z; Incesu RB; Karakiewicz P; Graefen M; Tilki D
Eur Urol; 2021 Oct; 80(4):400-404. PubMed ID: 34162491
[TBL] [Abstract][Full Text] [Related]
31. Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
Preisser F; Heinze A; S Abrams-Pompe R; Budäus L; Chun FK; Graefen M; Huland H; Tilki D
Prostate; 2022 Jun; 82(9):949-956. PubMed ID: 35344221
[TBL] [Abstract][Full Text] [Related]
32. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
33. Oncologic outcomes in prostate cancer patients treated with robot-assisted radical prostatectomy: results from a single institution series with more than 10 years follow up.
Bianchi L; Gandaglia G; Fossati N; Larcher A; Pultrone C; Turri F; Selli C; de Groote R; de Naeyer G; Borghesi M; Schiavina R; Brunocilla E; Briganti A; Montorsi F; Mottrie A
Minerva Urol Nefrol; 2019 Feb; 71(1):38-46. PubMed ID: 30547906
[TBL] [Abstract][Full Text] [Related]
34. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
35. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
36. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
[TBL] [Abstract][Full Text] [Related]
37. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
38. [Perioperative parameters and prognosis analysis of patients aged 80 years or older treated with radical prostatectomy for prostate cancer].
Zhang F; Zhang SD; Xiao CL; Huang Y; Ma LL
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):822-827. PubMed ID: 30337742
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
Doshi C; Vacchio M; Attwood K; Murekeyisoni C; Mehedint DC; Badkhshan S; Azabdaftari G; Sule N; Guru KA; Mohler JL; Kauffman EC
Prostate; 2016 Jun; 76(8):715-21. PubMed ID: 26880312
[TBL] [Abstract][Full Text] [Related]
40. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
